496MO Final overall survival results from the NICE-NEC trial (GETNE-T1913): A phase II study of nivolumab and platinum-doublet chemotherapy (CT) in untreated advanced G3 neuroendocrine neoplasms (NENs) of gastroenteropancreatic (GEP) or unknown (UK) origin

María Carmen Riesco Martínez, J. Capdevila Castillón, V. Alonso, P. Jimenez-Fonseca, A. Teule, Enrique Grande, I. Sevilla, M. Benavent, T. Alonso-Gordoa, A. Custodio, B. Antón Pascual, J. Hernando, E. Polo, Oscar Alfredo Castillo Trujillo, R. Garcia-Carbonero